source
- ARPA-H commits $62.7 million to develop FDA-authorized AI for heart-failure treatmentARPA-H announced a $62.7 million investment to create artificial-intelligence systems that can assist in treating heart failure. The program, called ADVOCATE, seeks to develop partially autonomous…
- AstraZeneca's COPD drug cuts flare-ups in late-stage trials, offering new option for patientsIn two late-stage studies, an AstraZeneca therapy showed a statistically significant reduction in acute exacerbations that worsen chronic obstructive pulmonary disease. The data, released on Tuesda…